Which of the following treatments involves an FDA-approved combination for smoking cessation?

Which of the following treatments involves an FDA-approved combination for smoking cessation?

• A. Nicotine patch and Nortriptyline
• B. Combination therapy using Varenicline and behavioral therapy
• C. Administering Bupropion alone
• D. Counseling without any medication

Answer: (B)

The treatment involving an FDA-approved combination for smoking cessation is indeed a combination of Varenicline and behavioral therapy. Varenicline is a medication specifically designed to help people stop smoking by reducing withdrawal symptoms and cravings. The addition of behavioral therapy complements this by providing strategies and support to change smoking behaviors and coping mechanisms. Behavioral therapy can significantly increase the success rate of quitting by addressing psychological aspects of addiction, thus making the combination of Varenicline and behavioral approaches a comprehensive method to facilitate smoking cessation. This combination is supported by research and guidelines set forth by health authorities due to its effectiveness. Other options represent individual treatments or combinations that do not fulfill the criteria for FDA-approved combinations specifically aimed at smoking cessation. For example, while combining the nicotine patch with Nortriptyline may seem effective, it is not an FDA-approved combination therapy recognized as a standard for smoking cessation. Similarly, while Bupropion can be effective alone for smoking cessation, it is not combined with any other therapy in the third option. Lastly, counseling without any medication, while beneficial, does not constitute an FDA-approved combination treatment that includes pharmacotherapy.

The treatment involving an FDA-approved combination for smoking cessation is indeed a combination of Varenicline and behavioral therapy. Varenicline is a medication specifically designed to help people stop smoking by reducing withdrawal symptoms and cravings. The addition of behavioral therapy complements this by providing strategies and support to change smoking behaviors and coping mechanisms.

Behavioral therapy can significantly increase the success rate of quitting by addressing psychological aspects of addiction, thus making the combination of Varenicline and behavioral approaches a comprehensive method to facilitate smoking cessation. This combination is supported by research and guidelines set forth by health authorities due to its effectiveness.

Other options represent individual treatments or combinations that do not fulfill the criteria for FDA-approved combinations specifically aimed at smoking cessation. For example, while combining the nicotine patch with Nortriptyline may seem effective, it is not an FDA-approved combination therapy recognized as a standard for smoking cessation. Similarly, while Bupropion can be effective alone for smoking cessation, it is not combined with any other therapy in the third option. Lastly, counseling without any medication, while beneficial, does not constitute an FDA-approved combination treatment that includes pharmacotherapy.